[
  {
    "ts": "2026-02-09T19:06:00+00:00",
    "headline": "Should You Buy Vertex Pharmaceuticals Before Feb. 12?",
    "summary": "The next 12 months will be important for the drugmaker.",
    "url": "https://www.fool.com/investing/2026/02/09/should-you-buy-vertex-pharmaceuticals-before-feb-1/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "61d83ea0-da18-30fa-89ad-0d44e37e3745",
      "content": {
        "id": "61d83ea0-da18-30fa-89ad-0d44e37e3745",
        "contentType": "STORY",
        "title": "Should You Buy Vertex Pharmaceuticals Before Feb. 12?",
        "description": "",
        "summary": "The next 12 months will be important for the drugmaker.",
        "pubDate": "2026-02-09T19:06:00Z",
        "displayTime": "2026-02-09T19:06:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/7f6799a82e6678eb70af6fe3ea83185b",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Patient talking to a doctor.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2OAMbWPB2D2jqBw7HyTqOA--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/7f6799a82e6678eb70af6fe3ea83185b.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G0S6h8amFw06Kj2kURe1YA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/7f6799a82e6678eb70af6fe3ea83185b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/09/should-you-buy-vertex-pharmaceuticals-before-feb-1/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/buy-vertex-pharmaceuticals-feb-12-190600084.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "INTC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-09T14:15:07+00:00",
    "headline": "Seeking Clues to Vertex (VRTX) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics",
    "summary": "Evaluate the expected performance of Vertex (VRTX) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.",
    "url": "https://finance.yahoo.com/news/seeking-clues-vertex-vrtx-q4-141507626.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "b07c889f-ef11-3c13-839f-9b8df1e915d2",
      "content": {
        "id": "b07c889f-ef11-3c13-839f-9b8df1e915d2",
        "contentType": "STORY",
        "title": "Seeking Clues to Vertex (VRTX) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics",
        "description": "",
        "summary": "Evaluate the expected performance of Vertex (VRTX) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.",
        "pubDate": "2026-02-09T14:15:07Z",
        "displayTime": "2026-02-09T14:15:07Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/0c6f98f4bf655bec3b199bc1a71b8b85",
          "originalWidth": 900,
          "originalHeight": 636,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/eN0EvS2DQjGO_6Aa8hYV4w--~B/aD02MzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0c6f98f4bf655bec3b199bc1a71b8b85.cf.webp",
              "width": 900,
              "height": 636,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IXPNK2bXbxtvuH6_.DBDbA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0c6f98f4bf655bec3b199bc1a71b8b85.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/seeking-clues-vertex-vrtx-q4-141507626.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/seeking-clues-vertex-vrtx-q4-141507626.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-09T23:13:10+00:00",
    "headline": "How Investors Are Reacting To Vertex (VRTX) Expanding Into Trispecific T-Cell Engagers For Autoimmune Diseases",
    "summary": "In early February 2026, WuXi Biologics announced a license and research service agreement granting Vertex Pharmaceuticals exclusive global rights to develop and commercialize a preclinical trispecific T-cell Engager for B-cell mediated autoimmune diseases, alongside contract R&D support on next-generation TCEs and potential milestone and royalty payments. This collaboration broadens Vertex’s autoimmune disease pipeline beyond its established cystic fibrosis franchise, adding an innovative...",
    "url": "https://finance.yahoo.com/news/investors-reacting-vertex-vrtx-expanding-231310948.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "0772117a-8a65-31d5-8aee-02748cda2f63",
      "content": {
        "id": "0772117a-8a65-31d5-8aee-02748cda2f63",
        "contentType": "STORY",
        "title": "How Investors Are Reacting To Vertex (VRTX) Expanding Into Trispecific T-Cell Engagers For Autoimmune Diseases",
        "description": "",
        "summary": "In early February 2026, WuXi Biologics announced a license and research service agreement granting Vertex Pharmaceuticals exclusive global rights to develop and commercialize a preclinical trispecific T-cell Engager for B-cell mediated autoimmune diseases, alongside contract R&D support on next-generation TCEs and potential milestone and royalty payments. This collaboration broadens Vertex’s autoimmune disease pipeline beyond its established cystic fibrosis franchise, adding an innovative...",
        "pubDate": "2026-02-09T23:13:10Z",
        "displayTime": "2026-02-09T23:13:10Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ihFoSuY9PLXURl2kI_sV.w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bIz6sh0rX4c7ACsVP8z51w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/investors-reacting-vertex-vrtx-expanding-231310948.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/investors-reacting-vertex-vrtx-expanding-231310948.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "WXIBF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]